152 related articles for article (PubMed ID: 19205754)
1. Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Adams LM; Johnson B; Zhang K; Yue L; Kirby LC; Lebowitz P; Stoltz R
Support Care Cancer; 2009 Sep; 17(9):1187-93. PubMed ID: 19205754
[TBL] [Abstract][Full Text] [Related]
2. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
Johnson B; Adams L; Lu E; Zhang K; Lebowitz P; Lates C; Blum R
Support Care Cancer; 2009 Sep; 17(9):1177-85. PubMed ID: 19205755
[TBL] [Abstract][Full Text] [Related]
3. Patient outcomes after therapeutic interchange of dolasetron for granisetron.
Steiner MA; Yorgason RZ; Vermeulen LC; Theisen J
Am J Health Syst Pharm; 2003 May; 60(10):1023-8. PubMed ID: 12789874
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.
Li SX; Pequignot E; Panebianco D; Lupinacci P; Majumdar A; Rosen L; Ahmed T; Royalty JE; Rushmore TH; Murphy MG; Petty KJ
J Clin Pharmacol; 2006 Jul; 46(7):792-801. PubMed ID: 16809805
[TBL] [Abstract][Full Text] [Related]
5. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dolasetron with coadministration of cimetidine or rifampin in healthy subjects.
Dimmitt DC; Cramer MB; Keung A; Arumugham T; Weir SJ
Cancer Chemother Pharmacol; 1999; 43(2):126-32. PubMed ID: 9923817
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
9. Effect of infusion rate on the pharmacokinetics and tolerance of intravenous dolasetron mesylate.
Dimmitt DC; Hunt TL; Spalitto AJ; Cramer MB; Shah AK; Arumugham T; Hahne W
Ann Pharmacother; 1998 Jan; 32(1):39-44. PubMed ID: 9475818
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
11. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
[TBL] [Abstract][Full Text] [Related]
12. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
[TBL] [Abstract][Full Text] [Related]
13. Single-dose, placebo-controlled, phase I study of oral dolasetron.
Dixon RM; Cramer M; Shah AK; Whitmore J; Benedict CR; Hahne WF
Pharmacotherapy; 1996; 16(2):245-52. PubMed ID: 8820468
[TBL] [Abstract][Full Text] [Related]
14. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
Bauman JW; Antal JM; Adams LM; Johnson BM; Murray SC; Peng B; Kirby LC; Lebowitz PF; Marbury TC; Swan S; Gutierrez M
Invest New Drugs; 2012 Apr; 30(2):662-71. PubMed ID: 21188466
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.
Dimmitt DC; Shah AK; Arumugham T; Cramer MB; Halstenson C; Horton M; Weir SJ
J Clin Pharmacol; 1998 Sep; 38(9):798-806. PubMed ID: 9753207
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1.
Dimmitt DC; Choo YS; Martin LA; Arumugham T; Hahne WF; Weir SJ
Biopharm Drug Dispos; 1999 Jan; 20(1):29-39. PubMed ID: 10086835
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Yanofsky R; Pritchard S; Leclerc JM; Howard DR; Perrotta M; Keays S; Pyesmany A; Dempsey E; Pratt CB
J Pediatr Hematol Oncol; 1999; 21(4):274-83. PubMed ID: 10445889
[TBL] [Abstract][Full Text] [Related]
20. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]